Neion Bio closes $23m Series A for egg-based biologics platform
Neion Bio has closed a $23 million Series A financing round, the company announced on 11 June 2026, with the round described as oversubscribed. Caffeinated Capital led the investment, joined by new participants Digitalis Ventures, Ensemble VC, and Trust Ventures, alongside follow-on commitments from existing backers Haystack and Basis Set Ventures. The proceeds will fund expansion of the company's pipeline across biosimilars, innovative medicines, critical reagents, and animal health.
The New York-based company, founded in 2024, emerged from stealth in March 2026 and has also disclosed a commercial co-development and supply agreement with an unnamed major pharmaceutical company. That deal centres on a multi-product biosimilars collaboration targeting global markets, though financial terms were not disclosed.
The Raptor platform
Neion's core technology, branded the Raptor platform, uses precision genetic engineering to introduce recombinant protein production into fertilised chicken eggs, restricting expression to the egg white. The company argues that eggs represent a biologically optimised vessel for producing large quantities of complex, glycosylated proteins in a sterile environment, offering advantages in scalability, capital efficiency, and cost compared with conventional mammalian cell culture or microbial fermentation systems.
Co-founder and chief technology officer Sam Levin said the platform is "built on the belief that the future of biomanufacturing will come not from forcing biology into increasingly complex industrial systems, but from harnessing biological systems already optimised by evolution itself." The company also says the platform can enable meaningful-scale production within days, which it positions as a significant advantage for rapid screening and iteration cycles.
Chief executive Dimi Kellari framed the round in the context of broader advances in genetic engineering tools, describing an opportunity to "fundamentally reshape" biologics manufacturing. Varun Gupta, partner at Caffeinated Capital, cited domestic supply chain resilience as a key strategic rationale for the investment.
Market context
Egg-based biologics production is not entirely new: the technology underpins seasonal influenza vaccine manufacturing, where it has been used at industrial scale for decades. Neion's differentiation lies in applying modern precision genetic engineering tools to extend this approach to complex therapeutic proteins and biosimilars, a considerably more demanding class of molecules in terms of post-translational modification requirements.
The broader biologics contract development and manufacturing organisation market is crowded, with established players including Lonza, Samsung Biologics, and Fujifilm Diosynth Biotechnologies operating at multi-tonne scale using Chinese hamster ovary cell systems. Neion's pitch is cost and speed rather than immediate volume capacity, which positions it more as a platform technology licensor and co-development partner than a direct competitor to large-scale CDMOs in the near term. The unnamed pharma co-development agreement suggests the company is already testing that commercial model.
The round's oversubscription, and the involvement of deep-technology-oriented funds alongside life science specialists, reflects continued investor appetite for platform-level innovation in bioprocessing, a sector that has drawn renewed attention in the United States amid ongoing policy debates around domestic pharmaceutical supply chain security. Whether Neion's egg-based approach can achieve the consistency and regulatory acceptance required for complex biologics at commercial scale remains the central open question for the platform.